Tag: liabilities

PHILADELPHIA, June 17, 2025 (GLOBE NEWSWIRE) -- Brandywine Realty Trust (the “Company”) (NYSE: BDN) announced today that its operating partnership, Brandywine Operating Partnership, L.P. (the “Operating Partnership”), has priced an underwritten public offering of $150 million of its 8.875% guaranteed notes due 2029 (the “Notes”). Interest on the Notes will be payable semi-annually on April 12 and October 12 of each year, commencing on October 12, 2025.

INDIANAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Kite Realty Group Trust (NYSE: KRG) (the “Company”) announced today that, on June 17, 2025, its operating partnership, Kite Realty Group, L.P. (the “Operating Partnership”), priced an offering of $300 million aggregate principal amount of 5.200% Senior Notes due 2032 (the “Notes”) in an underwritten public offering. The Notes will be issued at 99.513% of par value with a yield to maturity of 5.281%. Interest on the Notes is payable semi-annually on February 15 and August 15 of each year, beginning on February 15, 2026. The offering is expected to close on June 27, 2025, subject to the satisfaction of customary closing conditions.

Fiscal 2025 Fourth Quarter Highlights:

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) (collectively, “Plains”) announced today that it has executed definitive agreements with Keyera Corp. (TSX: KEY) (“Keyera”) pursuant to which Plains will sell substantially all of its NGL business to Keyera for a total cash consideration of approximately $5.15 Billion CAD ($3.75 Billion USD).

Transaction highlights strategic execution and unlocks capital for highly accretive Spetner Acquisition

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“APA”) entered with Paladin Pharma Inc., an Endo, Inc. operating company, as announced in March 2025.

Execution of sustained organic growth in Canada, certain U.S. states, France, and the United Kingdom, derived from high quality pipeline of projects and growth path totaling 8 GW